Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:37 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 21,010 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Biospecimens for Novel Research Uses

NCT03848962
View directory record Official record
Conditions
Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Interventions
Not listed
Lead sponsor
iSpecimen Inc
Industry
Eligibility
1 Month to 89 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Huntsville, Alabama • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Nov 1, 2026, 5:37 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 1, 2026, 5:37 PM EST
Completed Not applicable Interventional Results available

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

NCT00595361
View directory record Official record
Conditions
Asthma
Interventions
salmeterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Berkeley, California • Burbank, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Nov 1, 2026, 5:37 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity

NCT01158573
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

NCT00041769
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic Drug Monitoring (TDM)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Nov 1, 2026, 5:37 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03533283
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Glofitamab, Atezolizumab, Obinutuzumab, Tocilizumab, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Nov 1, 2026, 5:37 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

NCT04029688
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
Interventions
Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 30 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Nov 1, 2026, 5:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma

NCT02700542
View directory record Official record
Conditions
Asthma
Interventions
Integrated Pest Management
Other
Lead sponsor
New York City Department of Health and Mental Hygiene
Government
Eligibility
5 Years to 12 Years
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033, Placebo, Avonex
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Nov 1, 2026, 5:37 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pain Neuroscience Education for Depression

NCT04023435
View directory record Official record
Conditions
Chronic Low-back Pain, Depression
Interventions
PNE edcuation
Other
Lead sponsor
St. Ambrose University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 4 Interventional

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

NCT00002376
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:37 PM EST
Completed Not applicable Interventional

A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients

NCT00002050
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:37 PM EST
Not listed Phase 1 Interventional

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418
View directory record Official record
Conditions
Multiple Myeloma
Interventions
STI-1492
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Orange, California • Sacramento, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 1 Interventional

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

NCT00065390
View directory record Official record
Conditions
Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 2 Interventional

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT02176213
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Pomalidomide, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Ajai Chari
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Nov 1, 2026, 5:37 PM EST
Not listed Phase 1 Interventional

The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00005120
View directory record Official record
Conditions
HIV Infections
Interventions
Calanolide A
Drug
Lead sponsor
Sarawak MediChem Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 5:37 PM EST
Withdrawn Phase 1 Interventional

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

NCT03617224
View directory record Official record
Conditions
Cutaneous T-Cell Lymphomas
Interventions
TSEBT, TSEBT and pembrolizumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 1 Interventional

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, Richter Transformation Lymphoma, Burkitt Lymphoma, Lymphoplasmacytoid Lymphoma, T-cell Non-Hodgkin Lymphoma, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
Interventions
Zilovertamab vedotin
Drug
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 1, 2026, 5:37 PM EST
No Longer Available No phase listed Expanded access

Expanded Access for CC-4047

NCT03723096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-4047
Drug
Lead sponsor
Celgene
Industry
Eligibility
Not listed
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Nov 1, 2026, 5:37 PM EST
Completed Phase 3 Interventional Results available

Tezepelumab Home Use Study

NCT03968978
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab (APFS), Tezepelumab (AI)
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Hoover, Alabama • Gilbert, Arizona • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Nov 1, 2026, 5:37 PM EST
Withdrawn No phase listed Observational

Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

NCT04142385
View directory record Official record
Conditions
HIV Infection
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Medical Examination, Physical Examination, Proctoscopy with Biopsy, Questionnaire Administration
Other · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Nov 1, 2026, 5:37 PM EST